Clinical Trial Update: LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LME636 for relief of persistent ocular discomfort in severe dry eye disease; the study was completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• LME636

Snippet

Sponsor: Alcon, a Novartis Company | Conditions: Dry Eye | Phase 2 | Status: COMPLETED | Results posted: 2017-11-24